Solar Panels for
Pharmaceutical Plants
GMP Considerations
Specialist installations for pharmaceutical manufacturing. Clean room HVAC loads with 24/7 critical operations. Zero contamination risk, MHRA approved processes.
Pharmaceutical Energy Profile
Pharma facilities require constant climate control, clean room operations, and 24/7 critical systems
HVAC Systems
Clean room climate control & air handling
Critical Operations
Continuous sterile manufacturing
Clean Room Classes
Varying contamination control needs
Typical System
Large-scale for pharma plants
GMP Compliance & Installation Protocols
Critical Considerations
- Zero Contamination Risk: Roof work doesn't compromise clean rooms
- Shutdown Scheduling: Installation during planned maintenance windows
- MHRA Documentation: Full validation and change control procedures
- Critical Systems Protection: No disruption to sterile operations
Energy Breakdown
ROI for Pharmaceutical Manufacturing
High energy consumption makes pharma facilities ideal for solar investment
24/7 operations maximize solar ROI through constant daytime usage
Typical 300kW system for mid-size pharmaceutical plant
Significant grid electricity offset during production hours
EU GMP Annex 1 Compliance & Cleanroom Classifications
The revised EU GMP Annex 1 (implemented August 2023) fundamentally changes how contamination risk must be managed during facility modifications, including solar installations.
Contamination Control Strategy (CCS) Requirement
Under the 2023 revision, all sterile manufacturing facilities must maintain a documented Contamination Control Strategy. Any facility modification — including rooftop solar installation — must be assessed against this CCS and undergo formal change control review before works commence.
Ask the installer for a pre-installation assessment that includes: CCS gap analysis, risk assessment against EU GMP Annex 1 Section 4, particle baseline measurement (≥0.5μm and ≥5.0μm per ISO 14644-1), and formal change control documentation for your QA team.
Cleanroom Grade Impact Assessment
The EU GMP classification system grades cleanrooms A through D. Each grade requires different installation protocols when working on adjacent or overhead structures.
| EU GMP Grade | ISO Equivalent | Typical Use | Installation Protocol | Downtime Required |
|---|---|---|---|---|
| Grade A | ISO 5 | Aseptic fill/finish, open product | Works only during validated shutdown; full re-qualification required | Full facility shutdown |
| Grade B | ISO 7 (at rest) | Background to Grade A; aseptic prep | Isolated clean bay shutdown; positive pressure maintained | Partial shutdown by zone |
| Grade C | ISO 8 | Less critical sterile operations, filling buffer | Continuous particle monitoring; sequential zonal approach | Zonal shutdown only |
| Grade D | ISO 8+ | Non-sterile primary packaging, dispensing | Standard industrial protocols with containment barriers | Minimal/none |
GMP Installation Protocol
-
1
Pre-Works CCS Review: Formal change control submission to client QA team; risk assessment against applicable Annex 1 sections
-
2
Particle Baseline Measurement: ISO 14644-2 compliant pre-works sampling across all affected grades; data submitted to client QA
-
3
Sealed Penetration Works: All roof penetrations sealed with validated BS EN ISO 9001:2015 materials; pressure differential verification before and after
-
4
Post-Works Requalification: ISO 14644-2 particle count verification; HVAC pressure differential testing; filter integrity checks per EN 1822
-
5
IQ/OQ/PQ Documentation Package: Full validation dossier provided within 10 working days; MHRA audit-ready format
Validation Documentation Scope
Design specification conformance; component traceability certificates; calibration records for all metering equipment; as-built drawings to BS EN 62446-1:2016
System performance under normal/abnormal conditions; grid connection commissioning record per G99; protective relay test records; inverter performance verification
90-day monitored performance period; half-hourly generation data; export metering accuracy verification; yield ratio vs. modelled prediction (target ≥95% PR)
All computerised systems (monitoring, SCADA, generation analytics) documented per GAMP 5 Category 4/5 software guidelines where applicable
UK Pharmaceutical Manufacturing Clusters
The UK pharmaceutical sector operates across several defined manufacturing clusters, each with distinct energy profiles and solar potential.
Cheshire / Macclesfield Corridor
Home to AstraZeneca's global API manufacturing headquarters at Macclesfield, alongside Almac Group and Bayer facilities. Large-scale continuous manufacturing processes with 24/7 critical HVAC loads.
Cambridge Biomedical Campus
Europe's largest centre for medical research and health science. Continuous laboratory HVAC loads, autoclave cycles, and cold chain refrigeration drive high daytime electricity demand — ideally matched to solar generation profiles.
East Midlands Pharma Belt
Loughborough, Leicester, and Coventry host significant tablet/capsule manufacturing operations. Batch processing loads create predictable daytime energy demand peaks well-suited to solar offset.
Merseyside / North West
Liverpool and Warrington are home to contract manufacturing organisations (CMOs) and OTC pharmaceutical producers. Warrington's Almac facilities and Liverpool's biotech incubators represent growing solar opportunity.
Scotland (Ulverston / Irvine)
Dechra's Ulverston site and Irvine's established pharma cluster benefit from Smart Export Guarantee (SEG) payments alongside grid savings. Scotland's renewable electricity grid means lower carbon intensity for exported power.
Hertfordshire / Home Counties
Welwyn Garden City (GSK legacy sites), Hatfield, and Stevenage host a concentration of biopharma and diagnostics manufacturers. Proximity to London increases grid electricity costs, improving solar ROI.
Regulatory Compliance: MHRA, SECR & ESOS
Pharmaceutical manufacturers face a unique intersection of manufacturing quality regulation and energy/environmental reporting obligations.
MHRA GMP Compliance
Solar installation on licensed pharmaceutical manufacturing sites requires change control under the site's Pharmaceutical Quality System (PQS). Ask the installer how their process will integrate with your existing change management procedure.
- •Change control documentation to ICH Q10 standard
- •Risk assessment against EU GMP Chapter 3 (Premises)
- •Post-installation review documentation provided
- •All deviations captured and CAPA records provided
SECR Reporting Benefits
Streamlined Energy and Carbon Reporting (SECR) is mandatory for large UK companies (250+ employees or £36M+ turnover). Solar generation provides independently verifiable Scope 2 emission reductions.
- •Half-hourly generation data for SECR calculation
- •Scope 2 location-based and market-based metrics
- •Export metering data for consumed vs. exported split
- •Annual generation certificates for sustainability reports
ESOS Phase 4 Interaction
Most large pharmaceutical manufacturers qualify under ESOS Phase 4 (qualification date: 31 December 2026). Installing solar before the qualification date reduces your measured energy consumption baseline, which can affect the scope of required ESOS action plan measures.
- •Solar reduces kWh consumed in ESOS baseline period
- •Half-hourly metering satisfies ESOS evidence requirements
- •Demonstrates action against ESOS recommendations
- •Read our full ESOS Phase 4 solar guide
Science Based Targets & Net Zero Supply Chain Requirements
Major pharmaceutical companies are increasingly requiring Scope 3 supply chain emissions data as part of supplier qualification. If your facility supplies AstraZeneca, GSK, Pfizer, or other SBTi-committed companies, demonstrable Scope 2 reductions through solar generation can protect your supplier status.
SBTi-Committed Pharma Companies (Scope 3 Requirements):
- AstraZeneca — Ambition Zero Carbon target, Scope 3 supplier engagement
- GSK — net zero supply chain by 2030 programme
- Reckitt — Carbon Disclosure Project (CDP) supplier ratings
- Johnson & Johnson — Carbon Neutrality goal supplier requirements
Solar's Role in Supplier Compliance:
- Reduces Scope 2 market-based emissions (verifiable via EACs)
- Improves CDP score submitted in supplier questionnaires
- Demonstrates climate action in PSCI supplier audit framework
- Supports ISO 50001 energy management system certification
Frequently Asked Questions
Answers to technical and regulatory questions about solar at pharmaceutical sites.
Are solar installations GMP compliant for pharmaceutical facilities? ▼
Yes. Pharmaceutical solar installations are designed to meet GMP requirements under EU GMP Chapter 3 (Premises and Equipment) and MHRA standards. All installation procedures maintain clean room integrity through validated materials, sealed work areas, and continuous particle monitoring. Full IQ/OQ/PQ documentation is provided for regulatory audit. Zero contamination incidents across all pharmaceutical installations.
What does EU GMP Annex 1 (2022/2023) mean for solar installations? ▼
The revised EU GMP Annex 1 (August 2023 implementation) requires sterile manufacturers to maintain a documented Contamination Control Strategy (CCS). Any facility modification — including rooftop solar — must be formally assessed against this CCS. Ask each installer how the work would fit your change control process, for example a CCS gap analysis, formal change control submission, pre-works particle baseline measurement per ISO 14644-2 and post-installation requalification sampling, and what records they would supply for an MHRA inspection.
Can solar power critical clean room HVAC systems 24/7? ▼
Solar systems power pharmaceutical HVAC loads during daylight hours, with grid electricity maintaining operations overnight and on low-irradiance days. Systems are sized for continuous HVAC loads — clean room air handling (ISO 5-8 classifications), temperature/humidity control, and HEPA filtration. The grid connection is maintained as primary supply; solar provides offset rather than primary power, ensuring no risk to critical environmental controls. Typical 500kW–1MW installations offset 40–60% of annual HVAC energy costs.
What validation documentation is provided? ▼
Ask the installer for full IQ/OQ/PQ documentation. Installation Qualification (IQ) covers design specification, component traceability, and calibration records to BS EN 62446-1:2016. Operational Qualification (OQ) covers grid connection commissioning per G99 and inverter performance verification. Performance Qualification (PQ) covers a 90-day monitored performance period with half-hourly generation data. Ask for all computerised systems to be documented per GAMP 5 guidelines, and agree when the documentation will be handed over after commissioning.
How does solar interact with ESOS Phase 4 compliance? ▼
Most large pharmaceutical manufacturers qualify under ESOS Phase 4 (qualification date: 31 December 2026). Installing solar before this date reduces your measured energy consumption baseline, which can affect the scale of required ESOS action plan measures. Half-hourly metering data from the solar system satisfies ESOS evidence requirements for your lead energy assessor. Read the full ESOS Phase 4 solar compliance guide for detailed guidance.
What capital allowances are available for pharmaceutical solar? ▼
Solar panels are classified as special rate assets under s.104A Capital Allowances Act 2001 (HMRC CA23153). The primary relief is Annual Investment Allowance (AIA): 100% first-year deduction on the first £1 million of qualifying expenditure per tax year. For systems exceeding £1M, the 50% First Year Allowance (FYA, made permanent in Autumn 2023) applies to the excess. Full expensing does not apply to solar. See our detailed capital allowances guide for worked examples with your system size.
Get Matched Quotes for Solar at Your GMP Facility
Matched quotes for pharmaceutical manufacturing facilities
Pharmaceutical Manufacturing Solar Service Areas
We publish independent guidance on commercial solar panels for pharmaceutical manufacturing facilities and clean rooms across the UK, and we match quote enquiries with commercial solar installers.
London & South East
Midlands
North of England
For the broader picture, see how industrial solar panel systems compares with industrial solar energy — then request matched quotes from commercial solar installers and compare them like for like.
Continue Reading — Related Topics
Hand-picked guides covering the most relevant adjacent areas to this page.
By Industry / Sector
Regional & Commercial Guides
Solar power for medical manufacturers — UK pharmaceutical & cleanroom solar
UK pharmaceutical manufacturers and medical device producers are among the highest-load commercial electricity consumers in the country. Cleanroom HVAC alone (the air-handling units maintaining ISO Class 5–8 cleanrooms with HEPA filtration and tight humidity/temperature control) typically accounts for 40–60% of facility electricity use, running continuously 24/7. Combined with autoclave sterilisation, freeze-dry plant, and process cooling loads, a typical UK pharmaceutical manufacturing site uses 8–25 GWh of electricity per year — making solar PV a meaningful financial lever even before the ESG and Scope 2 reporting dimensions come into play.
Solar panel for medical manufacturers — typical installation profile
UK pharmaceutical manufacturing solar installations typically run 300 kW to 2 MW per site — the larger end driven by the high baseload of cleanroom HVAC, which produces self-consumption rates of 92–97% on a correctly-sized array. Project economics:
| Facility type | Typical kWh use | Solar system size | Annual saving |
|---|---|---|---|
| Small generics manufacturer | 3–5 GWh/yr | 300–500 kW | £75–£130k/yr |
| Mid-sized originator API plant | 8–15 GWh/yr | 500 kW–1 MW | £130–£260k/yr |
| Major formulation/fill-finish | 15–25 GWh/yr | 1–2 MW | £260–£500k/yr |
| Medical device manufacturing | 2–6 GWh/yr | 250–500 kW | £65–£130k/yr |
GMP plant setup in UK — solar & cleanroom integration
For UK pharmaceutical facilities operating under MHRA Good Manufacturing Practice (GMP) certification, the design and installation of rooftop solar PV requires specific consideration of the cleanroom environment below. Key integration points:
- Roof penetration control: any roof penetration risks compromising the cleanroom envelope. Modern non-penetrative ballasted mounting systems are the default for pharma solar installations to eliminate this risk entirely.
- Vibration isolation: compressor cycling and inverter switching can transmit vibration through roof structures into precision manufacturing or analytical instruments below. Vibration-damped mounting feet are specified for installations above analytical labs or precision filling lines.
- HVAC interaction: rooftop solar shading on roof-mounted AHU intakes can shift inlet air temperature by 2–4°C and affect cleanroom temperature stability. Array layouts maintain clear zones around HVAC plant.
- Validation impact: for GMP-validated environments, solar installation work is treated as a controlled change requiring an FDA-style Change Control assessment, impact assessment on validated systems, and re-qualification where appropriate. Most pharma solar installations are deemed "no impact" on validated processes but the assessment must be documented.
- Inspection-readiness: MHRA inspectors increasingly look at sustainability and supply-chain decarbonisation evidence during routine inspections. A documented on-site renewable generation programme is a competitive differentiator during inspection.
Solar for UK Pharmaceutical Manufacturing Sites
UK pharmaceutical and life-sciences clusters where solar PV is commonly deployed: Cambridge (AstraZeneca, GSK, Cambridge Science Park), Edinburgh (BioQuarter, Pfizer), Manchester (Alderley Park), Macclesfield (legacy AstraZeneca site, now Pyramid Plus), Stevenage (GSK), Slough (AstraZeneca), Barnard Castle (GSK), Dudley (Sterling Pharma Solutions), Cardiff (CatSci), and the Wrexham Industrial Estate cluster (Glaxo, Hyland Therapeutics). Each location has DNO-specific connection considerations (NGED west, Northern Powergrid north-east, UKPN south-east, etc.) that affect project lead times.
Solar pharm — funding routes for life sciences
Pharmaceutical and medical device manufacturers in the UK have access to the standard tax-relief stack (Annual Investment Allowance, 50% First-Year Allowance) which on a £600,000 typical pharma solar capital reduces the effective cost by £150,000. The Industrial Energy Transformation Fund (IETF), which historically supported decarbonisation at energy-intensive manufacturers, closed in July 2025 with no successor fund planned, so the tax-relief stack above is the realistic basis for a business case.
For mid-sized pharma and medical device manufacturers without large balance-sheet capacity, Power Purchase Agreements (PPAs) work well in this sector — the high self-consumption rate and 24/7 demand profile make PPA economics attractive to investors, and PPA tariffs 30–40% below grid for participating manufacturers are common.